A sustainable solid foam technology using capillary foams formed from biodegradable particles and curable bio-derived oils. Enables moldable, ultra-stable foams with mechanical strength and liquid resistance for industrial applications such as packaging and insulation.
This technology leverages capillary foams, a class of ultra-stable, moldable foams formed by frothing particle suspensions containing a small percentage of water-immiscible oil. By selecting biodegradable particles and curable bio-derived oils, the resulting solid foam offers a cost-effective, environmentally friendly alternative to conventional foam materials. The approach enables manufacturers to produce foams with tailored mechanical strength, water resistance, and oil resistance, suitable for applications in packaging, insulation, and other industrial uses where sustainability and performance are priorities.
Key features:
The capillary foam concept has been validated across multiple particle-oil systems, with published and unpublished work demonstrating stable foam formation, shape retention in lab molding, weight-bearing capability, and additive incorporation. Future work will focus on identifying particle and oil combinations that deliver target properties including degradability, stiffness, strength, and liquid resistance, using a modeling approach to guide component selection. Optimization of foaming, curing, and drying processes will ensure compatibility with existing manufacturing infrastructure such as extrusion and molding systems. The technology is at an early-to-mid stage of development, ready for collaborative research to advance component optimization and process scale-up.
Georgia Institute of Technology is a large, technology‑focused public research university in Atlanta with a strong applied research culture. Industry engages through the Georgia Tech Research Institute for contract R&D, a Midtown innovation district with co‑located corporate labs, and a statewide manufacturing extension to support scale‑up. A long‑standing partnership with a major academic medical center enables clinical translation, and a large co‑op program delivers a steady talent pipeline. Research is backed by competitive federal funding from NSF, NIH, DOE, DoD, and NASA. Technology commercialization is managed by the Georgia Tech Research Corporation, with dedicated licensing, corporate contracting, and startup support.